ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
R03DX05 | BioTech | Omalizumab - 75mg | 10818/945 | 163720/1 | XOLAIR | 75mg | 1 | Injectable solution | SC | Khalil Fattal & Fils S.A.L. | Vetter Pharma- Fertigung GmbH & Co KG | Germany | 19,154,571 L.L | 19.35 | D | Novartis Europharm Limited | Ireland | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
R03DX05 | BioTech | Omalizumab - 75mg | 10818 | 163720/1 | XOLAIR | 75mg | 1 | Injectable solution | SC | Khalil Fattal & Fils S.A.L. | Vetter Pharma- Fertigung GmbH & Co KG | Germany | 7,993,556 L.L | 19.35 | D | Novartis Europharm Limited | Ireland | 2/5/2024 | 70 |